Kyverna presents data update on KYV-101 CAR T therapy at EULAR symposium

Kyverna Therapeutics, Inc.

CEO Peter Maag introduced symposium; external speakers presented long-term clinical experience with anti-CD19 CAR T in autoimmune diseases.
KYV-101 data covered experience across multiple autoimmune diseases and sites, presented by James Chung, MD, PhD of Kyverna.
Panel discussion featured academic and Kyverna experts on KYV-101's potential in rheumatologic autoimmune indications.
No specific numerical efficacy or safety results were disclosed in the furnished presentation materials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.